Clinical Trial Update: Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma [NA]

View source ↗

Summary

Clinical trial update describing a first-line treatment using zanubrutinib, rituximab, and lenalidomide for Marginal Zone Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Brukinsa (zanubrutinib) (zanubrutinib)
• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: Zhengzhou University | Conditions: Marginal Zone Lymphoma(MZL) | NA | Status: NOT_YET_RECRUITING